Nice jump but this is just the beginning . Positive Phase 2 results of their Oral thin-film Insulin could send this low float stock over $10 easily .
-------
“Diabetes incidence is forecast to hit 500m people, globally, by 2025; with our partnered transbuccal insulin strip, MSL-001 is targeting a $20 billion market, adding significant revenue potential to our growing portfolio of products.”
Transbuccal Insulin – MidaForm™-Insulin-Pharmfilm®
Midatech’s most advanced research programme is focused on applying its GNP technology to develop a method of needle-free delivery of insulin for the treatment of diabetes. This programme takes advantage of the fact that binding a peptide hormone to a nanoparticle allows its absorption across the mucosa of the cheek.
Through its MidaSol Therapeutics joint venture with Monosol Rx, Midatech has developed a self-dissolving oral postage stamp-sized strip containing nanoparticle conjugated insulin referred to as MidaForm™-Insulin-PharmFilm®. This strip is placed on the inside of the cheek and the insulin is absorbed directly into the bloodstream via the mucous membrane of the cheek (i.e. transbuccal application). This mode of needle-free administration provides a more convenient, effective, safer and more discrete form of insulin delivery with faster onset. Midatech’s programme has the potential to offer an alternative to injections via needle for the treatment of diabetes patients.
From positive Phase I clinical trial results it has been demonstrated that the transbuccal insulin formulation is safe and well tolerated in healthy human volunteers and that it is absorbed faster and utilised more quickly than subcutaneous insulin.
•Phase I (2012) -No safety concerns
-Suggests insulin enters blood, faster to max effect
•Phase IIa-Completed in life phase January 2016
-Clinical Study Report is expected in April 2016
•Phase II data will inform strategic opportunities (license or exit)
